Radiomics
Insight-based
decision making
Diseases and
therapeutic areas
Industry
and Pharma
Healthcare
professionals
Scientific
researchers
About Radiomics
Radiomics is a next generation Liege-based imaging research organization built upon the unparallel experience of its founders, pioneers of the radiomics science.
Radiomics focuses on AI powered healthcare, with a unique expertise in Radiomics, Deep Learning & Federated Learning applied to oncology and other therapeutic areas. Through our proprietary advanced image analysis technology, we aim to unravel the gold mine of hidden data information embedded in standard medical images.
Our final goal is to support insight-based decision making for optimizing pharmaceutical and biotech companies’ clinical trials and drug development studies and for providing clinicians with a patient-centered approach based on personalized medicine. With this aim, Radiomics’ R&D team is continuously working on new solutions, in collaboration with multiple national and international partners.We can help you
Optimize
Your clinical trials (in terms of costs and time)
Detect
The subtlest signals of drugs efficacy and safety risk
Facilitate
Your crucial
go / no-go
decisions
go / no-go
decisions
Identify
Patients likely to respond to your treatment
Strengthen
Your points
in pay for outcome scenarios
in pay for outcome scenarios
Why Radiomics
Experience
Our scientists and clinicians are the ones who invented radiomics and have unparalleled experience and international recognition in this AI field.
Outreach
Radiomics has clients and partners in the EU, the US, Africa and Australia. Permanent presence in North America and China are in our plans for the near future.
IP Portfolio
Radiomics' comprehensive IP portfolio includes both granted and pending international (EU/US) patents.
People
Radiomics' team is composed of a multicultural and multidisciplinary set of people, specialized in a broad range of domains always enthusiastic in addressing clients and partner's needs.
Publications
Radiomics has numerous publications in high impact journals such as Nature Reviews, Clinical Oncology, Annals of Oncology and many more.
Latest news
whitepaper
- December 13th, 2021
Developing an imaging-based companion diagnostic tool with Radiomics
The second part in the series of articles about imaging-based companion diagnostics will focus on their development and is available to read here.
news
- December 1st, 2021
Radiomics joins the FNIH Biomarkers Consortium
Radiomics is proud to join the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC).
press
- November 25th, 2021
Radiomics announces the strategic support of OncoDNA in its prospective clinical trial SALMON
The two Belgian companies will work towards a better understanding of non-small cell lung cancer biology and characterization of the tumors using of AI technology
![[:swvar:ufile:1:description:]](/swfiles/files/logo-radiomics.svg?nc=1640345118){kind=logo}